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Background: Prevention of venous thromboembolism (VTE) in cancer patients remains controversial in most
clinical settings.
Purpose: The Italian Society for Haemostasis and Thrombosis (SISET) commissioned a project to develop clinical
practice guidelines for the prevention of VTE in patients with malignancy.
Methods: Key questions concerning the prevention of VTE in patients with malignancy were formulated by a
multidisciplinary working group consisting of experts in clinical medicine and research. After a systematic re-
viewand discussion of the literature, recommendationswere formulated and graded according to the supporting
evidence. For those questions for which the literature search did not ﬁnd any deﬁnitive answers (due to absence
of evidence, low quality evidence and/or contradictory evidence), a formal consensus method was used instead
to issue clinical recommendations.
Results: The search for “VTE prevention” resulted in 1021 citations; 69 articles were selected and 24 were used for
drafting clinical recommendations. Four areas were graded A to C: 1) Need of prevention (pharmacological and/or
mechanical) in cancer patients undergoingmajor abdominal or pelvic surgery and in 2) thosewith an acutemedical
disease requiring hospitalization and who are bedridden. Avoid prevention in 3) cancer patients with a central ve-
nous catheter and 4) those on chemotherapy, radiotherapy or hormonal therapy, except patients withmultiple my-
eloma treated with thalidomide/lenalidomide plus high-dose dexamethasone, and those with gastrointestinal or
lung cancer. Six areas were considered to be clinically important, but lacked evidence from the literature and thus
required a formal consensus (grade D): 1) need of prevention during chemo- radiotherapy or hormonal therapy in
patients with previous VTE; 2) optimal duration of pharmacological prevention in patients who are hospitalized/be-
dridden for acute medical illness; 3) optimal duration of pharmacological prevention in patients undergoing major
surgery other than abdominal and pelvic; 4) optimal duration of pharmacological prevention in myeloma patients
receiving thalidomide plus dexamethasone; 5) presence of cerebralmetastasis as a contraindication to pharmacolog-
ical prevention; 6) prevention in cancer patients undergoing surgery by laparoscopic procedures lastingN30min.
Conclusion: Results of the systematic literature review and an explicit approach to consensus techniques have led to
recommendations for the most clinically important issues in the prevention of VTE in cancer patients.
© 2011 Elsevier Ltd. All rights reserved.
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Introduction
Venous thromboembolism (VTE) occurs in up to 20% of cancer pa-
tients, and is one of the leading causes of death in patients with can-
cer [1,2]. Cancer cells can promote the activation of blood coagulation
directly by generating thrombin, or indirectly by stimulating endo-
thelial cells and circulating mononuclear cells to synthesise and ex-
press several procoagulant factors [3–5].
The risk of thrombosis differs across various cancer subgroups and
over the natural history of the disease. The risk of VTE is highest in the
initial period after the diagnosis of malignancy [6], but varies according
to the type ofmalignancy and stage of disease. This risk is also high even
in patients who may suffer from thrombocytopenia; indeed, recent
studies suggest a strong association with haematologic malignancies,
particularly lymphomas [6,7].
Cancer chemotherapy has been shown to amplify the procoagulant ef-
fect of cancer cells thus increasing the risk for thromboembolic complica-
tions [8,9]. Patients with cancer undergoing surgery have a two-fold
increased risk of postoperative deep vein thrombosis (DVT) and a three-
fold greater risk of developing a fatal pulmonary embolism (PE) com-
pared with patients who do not have cancer having similar surgery [10].
Results from numerous studies have identiﬁed the presence of a central
venous catheter (CVC) as a risk factor for developing upper-extremity
DVT [11], although discrepancies exist concerning the incidence of CVC-
related DVT and the efﬁcacy of pharmacological prophylaxis [12].
Unfortunately, the efﬁcacy and safety of the various prophylaxis
methods in these categories, as well as the need for prophylaxis
among particular patient groups, are not supported by adequate evi-
dence in different contexts, and there are considerably different ap-
proaches in clinical practice.
Considering this, the Italian Society for Haemostasis and Thrombosis
(SISET) commissioned a project to develop clinical practice guidelines
for the prevention of VTE in patients withmalignancies. The recommen-
dations were generated through a systematic literature search and for-
mulated accordingly with explicit methods for consensus development.
The objective of the present guidelines was to provide recommen-
dations for the prevention of VTE in cancer patients with particular
attention to the topic of chemotherapy-associated thrombosis and
areas of uncertainty.
Design and Methods
Methods
These guidelines were issued following a methodology previously
deﬁned by the SISET Guidelines Program Steering Group and ap-
proved by the SISET Executive Committee. Details on the methodolo-
gy have been published [13]. The ﬁrst literature search was
performed in December 2005, and updated searches were continued
until December 2010. The grading system adopted is the one
designed by the Scottish Intercollegiate Guideline Network (SIGN)
[14]. The draft recommendations were reviewed by an external
panel of two internationally recognized experts in the ﬁeld and the
SISET Executive Committee.
Panel composition
The SISET Executive Committee convened a multidisciplinary
working group consisting of experts in clinical medicine and research
relevant to the treatment of VTE in patients with cancer, including
medical and surgical oncologists.
The executive committee of SISET appointed one chairman (SS)
for the development of the present guidelines, and invited an expert
panel of 9 members from the society selected for their expertise in re-
search and clinical practice in the prevention of VTE (UA, MC, AF, DI,
ACM, DP, MS, MV, AV), one expert oncologist (FF) and one medical
practitioner (RL). The panel members are listed in Appendix 1.
The present guidelines focus on adult patients with active, solid and
haematological cancers, requiring chemo- radio- or surgical therapy or
in any other state that would potentially increase the risk for VTE (such
as being bedridden, insertion of CVC). The literature search was per-
formed using the MEDLINE (1966 to 2010) and EMBASE (1980 to
2010) electronic databases. For each topic, two reviewers selected studies
independently, with disagreements resolved through discussion and
with the opinion of a third reviewer, if necessary. Detailed information
on search strategies and results are available upon request. Selected arti-
cles were ranked according to a hierarchy of evidence levels, including
systematic reviews, controlled clinical trials, uncontrolled clinical trials
and case series. In the absence of evidence, a formal consensus method
was applied. A detailed description of the organization andmethodology
of the SISET guidelines is reported elsewhere [13].
Results
Searching for “VTEprevention” resulted in 1021 citations; 69 articles
were selected and 24 were used for drafting clinical recommendations.
Recommendations
1. Hospitalized patients with malignancies and concomitant acute
medical illness should receive prophylactic doses of LMWH or fon-
daparinux (grade A)
2. For those at a high risk of bleeding, or others with contraindica-
tions to pharmacological prophylaxis, mechanical prophylaxis
with intermittent leg compression or graduated stockings should
be provided (grade C)
3. In patients undergoing surgery for cancer, pharmacological pro-
phylaxis with UFH, LMWH or fondaparinux should be given for at
least 7 days (grade A)
4. In patients undergoing surgery for cancer, mechanical prophylaxis
can be given in addition to pharmacological prophylaxis (grade C)
5. In cancer patients undergoing surgery, pharmacological prophy-
laxis with unfractionated heparin (UFH) or LMWH should be ad-
ministered preoperatively (grade C)
6. In cancer patients undergoing surgery with major abdominal or
pelvic surgery, pharmacological prophylaxis with heparin or fon-
daparinux should be continued for 4 weeks (grade A)
7. In cancer patients with CVC, routine prophylaxis is not indicated
(grade A)
8. Mechanical prophylaxis is indicated in patients with an increased
risk of bleeding (grade C)
9. Pharmacological prophylaxis is not routinely recommended in pa-
tients undergoing chemotherapy or radiotherapy or hormonal
therapy (grade C) except in the following cases:
- patientswith lungor gastrointestinal cancer should receivenadroparin
(3,800 U anti-FXa daily) for no more than 4 months (grade A)
- patients with multiple myeloma treated with thalidomide or lena-
lidomide plus high-dose dexamethasone should receive LMWH or
aspirin or warfarin (Grade C)
Areas of uncertainty
Some areas of uncertainty have been discussed among experts
who deﬁned the following consensus grade:
1. Antithrombotic prophylaxis is appropriate in patients with previous
VTE who must receive chemotherapy, radiotherapy or hormone
therapy (grade D)
2. In cancer patients with concomitant acute medical illness, pharma-
cological prophylaxis up to 4 weeks is uncertain (grade D)
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3. In cancer patients undergoing surgery other than abdominal or
pelvic procedures, pharmacological prophylaxis for up to 4 weeks
is appropriate (grade D)
4. In patients receiving thalidomide/lenalidomide plus high dose
dexamethasone, pharmacological prophylaxis for up to 6 months
is appropriate (grade D)
5. In patients with cerebral cancer, pharmacological prophylaxis
(when needed) is appropriate (grade D)
6. Pharmacological or mechanical prophylaxis is appropriate in can-
cer patients undergoing laparoscopic procedures lastingN30 min.
(Grade D)
Literature review and analysis
Hospitalized patients
The reported frequency of VTE in hospitalized patients with cancer
ranges from 0.6% to 18% [7, 8]. Patients at a particularly high risk for
VTE include older patients, patients with cancers of the brain, pancre-
as, ovary, kidney, bladder, lung, GI tract, or with haematologic malig-
nancies, patients with metastatic disease, and those who are
immobilized, neutropenic, or infected. The risk of VTE increases sig-
niﬁcantly when patients with cancer are hospitalized [8].
Unfortunately, data regarding the efﬁcacy of primary prophylaxis for
reducing VTE in this group of cancer patients are lacking since most of
the information comes from non-cancer patients [15–19]. Three ran-
domized,multicentre studies investigating pharmacological prophylax-
is using either LMWH or fondaparinux in acutely-ill hospitalized
patients have been reported [15–17]. In all studies, patients with cancer
constituted a minority of the population, and only one provided out-
comedata for the cancer subset. Previous studies onmedical prophylax-
is using UFH (5,000 IU given twice daily) in acutely-ill medical patients
failed to demonstrate a signiﬁcant reduction in fatal PE [19], while in
other studies UFH given three times daily (5,000 IU) had the same efﬁ-
cacy of LMWH [20]. Recent guidelines on VTE prevention in cancer pa-
tients (ACCP guidelines, NCCN, ASCO, AIOM) strongly recommend (1A)
pharmacologic prophylaxis with either low-dose UFH or LMWH for
bedridden patients with active cancer, although these recommenda-
tions are based on clinical trials in which only a minority of patients
had cancer [21–25]. However, the low complication rates observed
with prophylaxis in the major medical trials appear to justify the use
of pharmacologic prophylaxis in hospitalized patients with cancer,
even if compliance with thromboprophylaxis is low [25].
Surgical Patients
The presence ofmalignant disease doubles the risk for DVT [26]with
reported incidences of asymptomatic calf vein thrombi of 40% to 80%,
proximal-vein thrombi 10% to 20%, PE 4% to 10% and fatal PE 1% to 5%
without perioperative thromboprophylaxis. The only factor inﬂuencing
the risk of VTE, other than those found in non-cancer patients (age=OR
2.6; duration of anaesthesia OR=4.5; prolonged postoperative immo-
bilization=OR 4.4, and history of a previous episode of VTE=OR 6.0),
is advanced stage of disease (OR 2.7) [26]. All patients undergoing
major surgical interventions for malignant disease (laparotomy, lapa-
roscopy, or thoracotomy lasting longer than 30minutes) are considered
to be at a high risk for developing VTE; thrombo-prophylaxis in the sur-
gical setting includes pharmacologic and mechanical methods [27].
Pharmacologic methods of thromboprophylaxis include UFH, LMWHs,
fondaparinux (an indirect inhibitor of activated factor Xa) and vitamin
K antagonists. Potential advantages favouring LMWHs over UFH in can-
cer surgery prophylaxis include once-daily versus t.i.d. injections and a
lower risk of heparin-induced thrombocytopenia [27]. Fondaparinux
was found to be at least as effective as dalteparin in preventing VTE in
a RCT (randomized clinical trial) of high-risk abdominal surgery pa-
tients (68% of the entire study population had cancer). A post-hoc
analysis suggested improved efﬁcacy in reducing VTE for fondaparinux
versus dalteparin in this large subgroup of patients with cancer [28].
Two recent randomized studies suggest that prolonging the dura-
tion of prophylaxis up to 4 weeks is more effective than a shorter du-
ration therapy in reducing postoperative VTE [29, 30]. In a RCT, VTE
rates were 4.8% in patients receiving enoxaparin for 4 weeks after
surgery for abdominal or pelvic cancer versus 12% in patients receiv-
ing enoxaparin for 1 week after surgery (pb0.02) [29]. In a second
randomized study, patients undergoing major abdominal surgery
were randomly assigned to receive either 4 weeks or 1 week of dalte-
parin prophylaxis. VTE rates were 16.3% in the 1-week arm compared
with 7.3% in the 4-week prophylaxis arm (pb0.012) [30]. More than
half of patients in each arm in this second study underwent cancer
surgery. There was no increase in bleeding complications associated
with prolonged prophylaxis in either study.
Regarding speciﬁc settings, there is little data regarding the bene-
ﬁt of thromboprophylaxis in patients undergoing laparoscopic sur-
gery, and none in the cancer population. In a large retrospective
study of patients with prostate cancer undergoing laparoscopic radi-
cal prostatectomy, the rate of symptomatic VTE was low (0.5%) [31].
In the absence of prospective data, however, standard prophylactic
regimens may be tailored to individual patient risk factors.
Mechanical methods can overcome venous stasis either passively
with graduated compression stockings, or actively with intermittent
pneumatic calf compression (IPC) or mechanical foot pumps. Recent
pooled analyses of studies of all three mechanical methods of throm-
boprophylaxis, evaluated in different patient populations, indicate
that as monotherapy these methods for VTE prevention reduce the
frequency of DVT by 66%, but only achieve a modest and insigniﬁcant
reduction of 31% in the frequency of PE [32]. A combined regimen of
pharmacologic and mechanical prophylaxis may improve efﬁcacy, es-
pecially in patients with the highest risk. A Cochrane review of 19
studies showed that low-dose UFH combined with graduated com-
pression stockings was four-times more effective for VTE prevention
than low-dose UFH alone [33].
Chemotherapy-associated thrombosis
There is limited data available regarding the prevention of VTE in
outpatients with cancer during chemotherapy.
In one study, Levine et al showed that low-dose warfarin is effec-
tive in reducing the rate of thrombosis during chemotherapy. In a
double-blind randomized trial, 311 patients with metastatic breast
cancer were given either very low dose warfarin (1 mg for 6 weeks,
subsequently adjusted to achieve a target INR of 1.3 to 1.9) or placebo
while receiving chemotherapy. The rate of thrombosis was 0.65% in
the warfarin arm and 4.4% in the placebo arm, a statistically-signiﬁ-
cant 85% risk reduction in the rate of VTE with no increase in bleeding
[34]. European investigators presented data in abstract form from two
double-blind, placebo-controlled RCTs (TOPIC-1 and TOPIC-2) in pa-
tients with metastatic breast cancer or stage III or IV non–small-cell
lung carcinoma. Patients were randomly assigned to receive either
6 months of the LMWH, certoparin (3,000 anti-factor Xa units daily)
or placebo for the primary prevention of chemotherapy-associated
VTE. In patients with breast cancer, there was no observed difference
in the rates of VTE (4%), whereas rates of major bleeding complica-
tions during the 6 months of treatment were 1.7% for the LMWH
arm and 0%for the placebo arm. In patients with lung cancer, there
was a non-signiﬁcant trend toward effectiveness of LMWH prophy-
laxis, with VTE rates of 4.5% for the LMWH arm and 8.3% for the pla-
cebo arm (p=0.07). Major bleeding in patients with lung cancer
occurred in 3.7% of LMWH treated patients versus 2.2% in the placebo
group. In a post-hoc analysis, rates of VTE in patients with stage IV
lung cancer who received LMWH were 3.5% compared with 10.1%
for those receiving placebo (p=0.03) [35].
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The risk of VTE in patients receiving thalidomide formultiplemyelo-
ma (MM) has been found to range from17% to 26% in combinationwith
dexamethasone [36, 37] and from12% to 28% in combinationwith other
chemotherapy agents including anthracyclines [38, 39]. Recent pro-
spective studies of thalidomide-containing regimens in patients with
MM have suggested the efﬁcacy of LMWH, warfarin at low ﬁxed doses
and aspirin for prophylactic anticoagulation. [38–44]. Palumbo et al
evaluated the safety and the efﬁcacy of LMWH or low-dose aspirin
(ASA) or low-ﬁxed dosewarfarin as anticoagulant prophylaxis in a sub-
analysis of 991 newly-diagnosed MM patients [42]. End-points were:
incidence of VTE, acute cardiovascular events, sudden death and
major and minor bleeding. Patients receiving thalidomide-containing
regimens were randomly assigned to receive LMWH (enoxaparin
40 mg/d, N=223) or ASA (aspirin 100 mg/d, N=227) or low-dose
warfarin (1.25 mg/d, N=223) for the duration of induction therapy,
while those receiving other anti-myeloma compounds were used as
controls. The incidence of VTE was 5% in the LMWH group, 6% in the
ASA group and 8% in the warfarin group (p=not signiﬁcant). VTEs
were 2% in the control group. Median time to onset of VTE for patients
who received LMWHorASAorwarfarinwas4.7, 2.4 and 2.4 months, re-
spectively. Cavallo et al evaluated the efﬁcacy of LMWH or low-dose
ASA as antithrombotic prophylaxis in 402MMpatients receiving lenali-
domide and low-dose dexamethasone [45]. End-points were: incidence
of VTE, acute cardiovascular events, death, major and minor bleeding.
All eligible patients were randomly assigned to receive LMWH (Enoxa-
parin 40 mg/d, n=166) or ASA (Aspirin 100 mg/d, n=176) for the du-
ration of the induction. During the induction phase, the overall
incidence of any thrombotic events was 1% in the LMWH group and
2,4% in the ASA group (p=0.45).Median time to the onset of thrombot-
ic events for patients who received LMWHor ASAwas 2.1 and 1 month,
respectively.
Agnelli et al. evaluated ambulatory patients with lung, gastrointesti-
nal, pancreatic, breast, ovarian, or head and neck cancer, whowere ran-
domly assigned in a double-blind manner to receive subcutaneous
injections of nadroparin (3,800 IU anti-Xa once a day, n=779) or place-
bo (n=387) [46]. Study treatment was given for the duration of the
chemotherapy for a maximum of 4 months. The primary outcome was
the composite of symptomatic venous or arterial thromboembolic
events, as assessed by an independent adjudication committee. All ran-
domised patients who received at least one dose of study treatment
were included in the efﬁcacy and safety analyses (modiﬁed intention-
to-treat population). A total of 1150 patients were included in the pri-
mary efﬁcacy and safety analyses: 769 patients in the nadroparin
group and 381 patients in the placebo group. 15 (2.0%) of 769 patients
treated with nadroparin and 15 (3.9%) of 381 patients treated with pla-
cebo had a thromboembolic event (single-sided, p=0.02). Five (0.7%)
of 769 patients in the nadroparin group and no patient in the placebo
group had amajor bleeding event (two-sided, p=0.18). The incidences
of minor bleeding were 7.4% (57 of 769) with nadroparin and 7.9% (30
of 381) with placebo. There were 121 (15.7%) serious adverse events in
the nadroparin goup and 67 (17.6%) serious adverse events in the place-
bo group.
CVC associated-thrombosis
The presence of a central venous catheter (CVC) predisposes cancer
patients to upper-extremity DVT [47–51]. In a recent meta-analysis,
nine RCTs were evaluated [52]. The use of heparin in cancer patients
with CVCwas associatedwith a trend towards a reduction in symptom-
atic DVT [relative risk (RR)=0.43; 95% conﬁdence interval (CI): 0.18 to
1.06], but the data did not show any statistically signiﬁcant effect on
mortality (RR=0.74; 95% CI: 0.40 to 1.36), infection (RR=0.91; 95%
CI: 0.36 to 2.28), major bleeding (RR=0.68; 95% CI: 0.10 to 4.78) or
thrombocytopenia (RR=0.85; 95% CI: 0.49 to 1.46). The effect of warfa-
rin on symptomatic DVT was not statistically signiﬁcant (RR=0.62;
95% CI: 0.30 to 1.27). When studies assessing different types of
anticoagulants were pooled, symptomatic DVT rates were signiﬁcantly
reduced (RR=0.56; 95% CI: 0.34 to 0.92) [53]. Although this area re-
mains controversial, prophylactic doses of LMWH cannot be recom-
mended as thromboprophylaxis for cancer patients with indwelling
CVCs, except in particular situations (such as previous thrombosis or
additional known individual risk factors) [12,53].
Discussion
Patients with cancer represent a high-risk population for VTE al-
though its prevention remains a challenge in terms of both treatment-
associated toxicities and scarcely-available evidence. Notwithstanding
these limits, in the last years at least three guidelines have been pub-
lished addressing VTE prevention in cancer patients. The ACCP guide-
lines on antithrombotic and thrombolytic therapy included chapters
on the prevention and treatment of VTE [21–25], but did not focus spe-
ciﬁcally on cancer patients, even if selected issues related to patients
with cancer were discussed. The National Comprehensive Cancer Net-
work (NCCN) VTE Panel was convened in 2005, and its most recent
guidelines were published in 2008 [21]. All aspects of VTE (prophylaxis,
treatment and related-complications) were discussed and presented in
ﬂow-charts; some issues, however, were not discussed but left to fur-
ther evidence from clinical trials (such as VTE prophylaxis in patients
with prolonged thrombocytopenia, VTE prophylaxis in patients with
history of CVC-related DVT and extended VTE prophylaxis in medical
oncology patients). The ASCO committed a comprehensive systematic
review of the medical literature on the prevention and treatment of
VTE in cancer patients; the comprehensive search included the use of
electronic databases through the end of 2006. These guidelines focused
the need of antithrombotic prophylaxis in selected settings: 1) hospital-
ized patientswith cancer, 2) those receiving systemic chemotherapy, 3)
those undergoing surgery and, ﬁnally, 4) the impact of anticoagulants
on cancer patient survival [24]. The ItalianAssociation ofMedical Oncol-
ogy (AIOM)has published recommendations to instruct clinical practice
in the management of VTE in patients with cancer [23]. These recom-
mendations are comprehensive and focus on six different aspects, in-
cluding VTE associated with occult cancer, prophylaxis of VTE in
cancer surgery, prophylaxis of VTE during chemotherapy or hormonal
therapy, prophylaxis of VTE associated with central venous catheters,
treatment of VTE in patients with cancer, and anticoagulation and prog-
nosis of cancer. A recent update of the AIOM guidelines has been pub-
lished, but it contains only a few recommendations regarding VTE
prophylaxis [22,23].
Our guideline offers explicit recommendations for the use of antic-
oagulation and othermeasures for the prevention of VTE in hospitalized
patients with cancer and those receiving cancer chemotherapy on an
ambulatory basis, patients with cancer in the perioperative and postop-
erative period and those with recent VTE. We also give recommenda-
tions on areas of uncertainty that meet clinically important issues,
such as patients with previous VTE who are eligible for chemotherapy,
radiotherapy or hormone therapy, duration of VTE prophylaxis in med-
ical cancer patients, subgroups of cancer patients who are candidates
for low-risk surgical approaches, or those with cerebral cancer who re-
quire pharmacological antithrombotic prophylaxis. Nevertheless, the
available data addressing these and related issues are limited, and
there still remains the need for additional research, particularly in the
form of large, well-designed, randomized, controlled clinical trials.
In conclusion, hospitalized patientswith cancer should be considered
candidates for VTE prophylaxis in the absence of speciﬁc contraindica-
tions, such as active bleeding, even if the recommendations for VTE pro-
phylaxis are based on clinical trials that enrolled, in most cases, only a
small proportion of patients with cancer. There is little data available re-
garding the prevention of VTE in outpatients with cancer. Additional
studies are needed to further evaluate the potential risk of VTE and the
value of primary prophylaxis in patients receiving novel targeted thera-
pies, particularly the class of antiangiogenic agents.
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Regarding major surgical intervention for malignant disease, all
patients should be considered for thromboprophylaxis for at least
7 days postoperatively; prolonged prophylaxis for up to 4 weeks may
be considered in high-risk patients, even if additional studies are need-
ed to better deﬁne the risk-beneﬁt proﬁle of prolonged anticoagulation.
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